

DAFTAR PUSTAKA

- Abg Abd Wahab, D.Y., Arshad, N., Ahmad, W. and Mohd Tohid, S.F. (2019) ‘Review on cross talk between neurotransmitters and neuroinflammation in striatum and cerebellum in the mediation of motor behaviour’, *BioMed Research International*, 2019, pp. 1–17. doi: 10.1155/2019/1767203.
- Adamu, A., Thomas, P., James, S. and Gur, B. (2023) ‘Epilepsy in Asian countries’, *Acta Epileptologica*, 5(1), pp. 1–12. doi: 10.1186/s42494-023-00136-1.
- Amarante-Mendes, G.P., Adjemian, S., Branco, L.M. and Barbé-Tuana, F.M. (2018) ‘Pattern recognition receptors and the host cell death molecular machinery’, *Frontiers in Immunology*, 9(OCT), pp. 1–19. doi: 10.3389/fimmu.2018.02379.
- Andersson, Å., Covacu, R., Sunnemark, D., Almgren, M., Lassmann, H. and Harris, R.A. (2008) ‘Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis’, *Journal of Leukocyte Biology*, 84(5), pp. 1248–1255. doi: 10.1189/jlb.1207844.
- Andersson, U., Yang, H. and Harris, H. (2018) ‘Extracellular HMGB1 as a therapeutic target in inflammatory diseases’, *Expert Opinion on Therapeutic Targets*, 22(3), pp. 263–277. doi: 10.1080/14728222.2018.1439924.
- Aninditha, T. and Wiratman, W. (2017) *Buku Ajar Neurologi*. 1st edn. Jakarta: Departemen Neurologi Fakultas Kedokteran Indonesia.
- Arslan, G. and Demir, B. (2022) ‘Cognitive impairment in epilepsy patients and its correlations’, *Applied Neuropsychology: Adult*. doi: 10.1080/23279095.2022.2133606.
- Asnakew, S., Haile, M.K., Birhanu, A.M. and Mekonnen, D. (2022) ‘Cognitive adverse effects of epilepsy and its predictors attending outpatient department of South Gondar zone hospitals, Amhara Region, Ethiopia 2020/2021’, *PLoS ONE*, 17(12), pp. 1–13. doi: 10.1371/journal.pone.0278908.
- Baars, B.J. and Gage, N. (2010) *Kognisi, Otak, dan Kesadaran: Pengantar Ilmu Saraf Kognitif*. New York: Pers Akademik.
- Banote, R.K., Akel, S. and Zelano, J. (2022) ‘Blood biomarkers in epilepsy’, *Acta Neurologica Scandinavica*, 146(4), pp. 362–368. doi: 10.1111/ane.13616.
- Brodie, M.J., Kwan, P. and Sills, G.J., 2017. *Epilepsy: A Clinical Guide*. BMJ.
- Camfield, P. and Camfield, C. (2015) ‘Incidence, prevalence and aetiology of

- seizures', *Epileptic Disord*, 17(2), pp. 117–123.
- Chai, X., Li, Y., Zhang, X., Wu, X. and Sun, Y. (2023) 'Cognitive impairment as a comorbidity of epilepsy in older adults: Analysis of global and domain-specific cognition', *Epileptic Disord*, 25, pp. 65–73.
- Chen, Z., Gao, Y. and Wu, Q. (2023) 'Epidemiology of epilepsy and seizures', *Frontiers in Epidemiology*, 3(August), pp. 1–3. doi: 10.3389/fepid.2023.1273163.
- Chen, R., Kang, R., and Tang, D. (2022) 'The mechanism of HMGB1 secretion and release', *Journal Title*, 1(1), pp. 1-1. doi: [insert DOI if available].
- Costagliola, G., Depietri, G., Michev, A., Riva, A., Foiadelli, T., Savasta, S., Bonuccelli, A., Peroni, D., Consolini, R., Marseglia, G.L., Orsini, A. and Striano, P. (2022) 'Targeting inflammatory mediators in epilepsy: A systematic review of its molecular basis and clinical applications', *Frontiers in Neurology*, 13. Available at: <https://doi.org/10.3389/fneur.2022.741244> (Accessed: 18 October 2024).
- Dahlan, S. (2017) *Statistik untuk Kedokteran dan Kesehatan*. 3rd edn. Jakarta: Salemba Medika. Available at: <https://doku.pub/download/statistik-untuk-kedokteran-dan-kesehatan-msopiyudin-dahlan-30j8pxk4p5lw>.
- Dai, S., Zheng, Y., Wang, Y., Sun, S. and Li, Y. (2021) 'HMGB1, neuronal excitability and epilepsy', *Acta Epileptologica*, 3(13). doi: 10.1186/s42494-021-00048-y.
- Elhady, M., Youssef, T., Hafez, M. and Soliman, M. (2021) 'Circulating glial fibrillary acidic protein and ubiquitin carboxy-terminal hydrolase-L1 as markers of neuronal damage in children with epileptic seizures', *Child's Nervous System*, 37(3), pp. 879–884. doi: 10.1007/s00381-020-04920-z.
- Epilepsy Foundation New England (2024) 'Women & Epilepsy'. Available at: <https://epilepsynewengland.org/knowledge-center/women-epilepsy>.
- Engel, J., & Pedley, T. A. (Eds.). (2008). *Epilepsy: A Comprehensive Textbook*. Lippincott Williams & Wilkins.
- Fatmi, K.N., Dewi, D.R.L. and Ilmiawan, M.I. (2022) 'Hubungan lama menderita, frekuensi kejang dan keteraturan konsumsi OAE terhadap fungsi kognitif pada pasien epilepsi', *Jurnal Nasional Ilmu Kesehatan (JNIK)*, 4, pp. 52–65.
- Fisher, R.S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J.H., Elger, C.E., Engel, J. et al. (2014a) 'A practical clinical definition of epilepsy', *Epilepsia*, 55(4), pp. 475–482. doi: 10.1111/epi.12550.

- Fisher, R.S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J.H., Elger, C.E., Engel, J. et al. (2014b) 'ILAE official report: A practical clinical definition of epilepsy', *Epilepsia*, 55(4), pp. 475–482. doi: 10.1111/epi.12550.
- Frank, M.G., Weber, M.D., Watkins, L.R. and Maier, S.F. (2015) 'Stress sounds the alarmin: The role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory priming', *Brain, Behavior, and Immunity*, 48, pp. 1–7. doi: 10.1016/j.bbi.2015.03.010.
- Fu, L., Liu, K., Wake, H., Teshigawara, K., Yoshino, T., Takahashi, H. and Mori, S. (2017) 'Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpine-induced status epilepticus in mice', *Scientific Reports*, 7(1), pp. 1–13. doi: 10.1038/s41598-017-01325-y.
- Fujita, K., Motoki, K., Tagawa, K., Chen, X., Hattori, S. and Iwatubo, T. (2016) 'HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease', *Scientific Reports*, 6(June), pp. 1–5. doi: 10.1038/srep31895.
- Gavrilovic, A., Jovic, N., Mijajlovic, M., Pavlovic, D., Zivanovic, I. and Veselinovic, I. (2019) 'Impact of epilepsy duration, seizure control and EEG abnormalities on cognitive impairment in drug-resistant epilepsy patients', *Acta Neurologica Belgica*, 119(3), pp. 403–410. doi: 10.1007/s13760-019-01090-x.
- Gonzalez, A., Cheng, Y., & Liu, J. (2014) 'Sex differences in response to stress and inflammation', *Nature Reviews Endocrinology*, 10(10), pp. 606-618.
- Gonzalez, A., Bansal, R., & Gupta, A. (2016) 'Sex differences in autoimmune diseases', *Clinical Reviews in Allergy & Immunology*, 51(2), pp. 172-179.
- Gong, W., Liu, Y., Wang, C., Zhang, H., and Liu, Y. (2010) 'The anti-inflammatory activity of HMGB1 A box is enhanced when fused with C-terminal acidic tail', *Journal of Biomedicine and Biotechnology*, 2010, 915234.
- Harahap, H.S., Rizki, M. and Irawati, D. (2022) 'Factors associated with global cognitive impairment in epilepsy patients: a cross-sectional study in Mataram, Indonesia', *Medical Journal of Indonesia*, 31(3), pp. 155–159. doi: 10.13181/mji.oa.226118.
- Harvey, P.D. (2019) 'Domains of cognition and their assessment', *Dialogues in Clinical Neuroscience*, 21(3), pp. 227–237. doi: 10.31887/DCNS.2019.21.3/pharvey.
- He, H.J., Wang, Y., Le, Y., Duan, K.M., Xie, J., Yan, X.H. and Zhang, W. (2012)

- ‘Surgery upregulates high mobility group box-1 and disrupts the blood-brain barrier causing cognitive dysfunction in aged rats’, *CNS Neuroscience and Therapeutics*, 18(12), pp. 994–1002. doi: 10.1111/cns.12018.
- Hermann, B.P., Seidenberg, M. and Jones, J.E., 2009. Neuropsychological aspects of epilepsy. *Epilepsia*, 50(Suppl. 3), pp.17-23.
- Holmes, G.L. (2015) ‘Cognitive impairment in epilepsy: the role of network abnormalities’, *Epileptic Disord*, 17(2), pp. 101–116. doi: 10.1002/acn3.503.
- Hu, Y., Liu, Y., Chen, Y. and Wang, J. (2021) ‘Gender and socioeconomic disparities in global burden of epilepsy: an analysis of time trends from 1990 to 2017’, *Frontiers in Neurology*, 12(April), pp. 1–10. doi: 10.3389/fneur.2021.643450.
- Huang, Q., Zhang, J., Sun, Y., Gao, X., Sun, D. and Dong, X. (2020) ‘Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis’, *Cellular and Molecular Biology*, 66(3), pp. 39–47.
- Huff, J.S. and Fountain, N.B. (2011) ‘Pathophysiology and definitions of seizures and status epilepticus’, *Emergency Medicine Clinics of North America*, 29(1), pp. 1–13. doi: 10.1016/j.emc.2010.08.001.
- Husein, N., Lumempouw, S.F. and Ramli, Y. (2010) ‘Montreal Cognitive Assessment versi Indonesia MoCA-Ina untuk skrining gangguan fungsi kognitif’, *Neurona*.
- Hussain, B., Fang, C. and Chang, J., 2021. Blood–Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia. *Frontiers in Neuroscience*, 15, p.688152. Available at: <https://doi.org/10.3389/fnins.2021.688152>.
- Ikawati, Z., Wijayatri, R. and Ghofir, A. (2015) ‘The comparison between monotherapy and polytherapy in epilepsy idiopathic generalised tonic clonic’, *Journal of Management and Pharmacy Practice*, 3(2), pp. 93–98.
- Kan, M., Yao, Y., Wang, Y. and Li, X. (2019) ‘Circulating high mobility group box-1 and toll-like receptor 4 expressions increase the risk and severity of epilepsy’, *Brazilian Journal of Medical and Biological Research*, 52(7), pp. 1–7. doi: 10.1590/1414-431x20197374.
- Kaneko, Y., Tanaka, K., Chiba, S., Maki, K. and Kuroda, S. (2017) ‘Extracellular HMGB1 modulates glutamate metabolism associated with kainic acid-induced epilepsy-like hyperactivity in primary rat neural cells’, *Cellular Physiology and Biochemistry*, 41(3), pp. 947–959. doi: 10.1159/000460513.

- Kiely, K. (2014) ‘Cognitive function’, in Encyclopedia of Quality of Life and Well-Being Research. Dordrecht: Springer Netherlands, pp. 2071–2079.
- Kim, S.Y., Park, J., Lee, H., Hong, J.H. and Moon, K. (2017) ‘TGF β signaling is associated with changes in inflammatory gene expression and perineuronal net degradation around inhibitory neurons following various neurological insults’, *Scientific Reports*, 7(1), pp. 1–14. doi: 10.1038/s41598-017-07394-3.
- Kusumastuti, K., Gunadharma, S. and Kustiowatu, E. (2019) Pedoman Tatalaksana Epilepsi. Surabaya: Airlangga University Press.
- Kwan, P., Arzimanoglou, A., Berg, A.T., Brodie, M.J., Allen Hauser, W., Mathern, G., Moshé, S.L., Perucca, E. and Wiebe, S. (2010) ‘Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies’, *Epilepsia*, 51(6), pp. 1069–1077. doi: 10.1111/j.1528-1167.2009.02397.x.
- Landi, S., Mazzon, E., Cappello, F., Biagini, G. and Blandini, F. (2019) ‘Transient cognitive impairment in epilepsy’, *Frontiers in Molecular Neuroscience*, 11(January), pp. 1–15. doi: 10.3389/fnmol.2018.00458.
- Lestari, N.D., Ramadhani, M., Yusuf, M. and Firdaus, W. (2020) ‘Factors affecting the mini-mental state examination (MMSE) score in the epilepsy patients in Aceh, Indonesia’, *Bali Medical Journal*, 9(1), pp. 185–188. doi: 10.15562/bmj.v9i1.1736.
- Lenehan, M.E., Summers, M.J., Saunders, N.L.J., Summers, J.J., Ritchie, K. and Vickers, J.C., 2015. Relationship between education and age-related cognitive decline: a review of recent research. *Neuropsychology Review*, 25(2), pp.201-211.
- Liang, K.G., Zhang, W., Jiang, S.H. and Wang, W.J. (2019) ‘Increased serum S100B levels in patients with epilepsy: A systematic review and meta-analysis study’, *Frontiers in Neuroscience*, 13(MAY), pp. 1–11. doi: 10.3389/fnins.2019.00456.
- Liebner, S., Gerhardt, H., Wolburg, H., Burger, A., Euler, U., Fuchs, E. and Gnirs, R. (2018) ‘Functional morphology of the blood–brain barrier in health and disease’, *Acta Neuropathologica*, 135(3), pp. 311–336. doi: 10.1007/s00401-018-1815-1.
- Li, Q., Zhang, Z. and Fang, J. (2024) ‘Hormonal changes in women with epilepsy’, Department of Neurology, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, Zhejiang Province, China; Department of Neurology, The Mianyang Central Hospital, Mianyang, Sichuan Province, China.

- Lu, B., Wang, J., Luo, Y., Wang, J., and Yang, J. (2014) ‘Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review’, *Expert Review of Clinical Immunology*, 10(6), pp. 713–727.
- Mameniskiene, R., Jatuzis, D., and Kaubrys, G., 2006. Cognitive impairment in epilepsy. *Advances in Psychiatric Treatment*. Available at: <https://www.cambridge.org/core/journals/advances-in-psychiatric-treatment>
- Maroso, M., Balosso, S., Ravizza, T., Liu, J., Aronica, E., Iyer, A.M., Limatola, C., Vezzani, A. (2010) ‘Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures’, *Nature Medicine*, 16(4), pp. 413–419. doi: 10.1038/nm.2127.
- Mawuntu, A.H.P., Nugraha, D., Widodo, S. and Anggraini, R. (2020) ‘Anti-epileptic drugs adherence of epilepsy patients in Indonesia’, *International Journal of Community Medicine and Public Health*, 7(6), p. 2082. doi: 10.18203/2394-6040.ijcmph20202456.
- Mondello, S., Gabrielli, A., Catani, S., D’Ippolito, M., Tortorella, C., Alexandrova, R., Jeromin, A. (2012) ‘Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure’, *BMC Neurology*, 12, pp. 1–7. doi: 10.1186/1471-2377-12-85.
- Mo, J., Hu, J., & Cheng, X. (2023). The role of high mobility group box 1 in neuroinflammatory related diseases. *Biomedicine & Pharmacotherapy*, 161, 114541. <https://doi.org/10.1016/j.biopha.2023.114541>
- Naglova, H. and Bucova, M. (2012) ‘HMGB1 and its physiological and pathological roles’, *Bratisl Lek Listy*, 116(5), pp. 296–301. doi: 10.4149/BLL.
- Nasreddine, Z.S., Phillips, N.A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J.L. and Chertkow, H. (2005) ‘The Montreal Cognitive Assessment (MoCA): A brief screening tool for mild cognitive impairment’, *Journal of the American Geriatrics Society*, 53(4), pp. 695–699.
- Ngadimon, I.W., Mohan, D., Shaikh, M.F., Khoo, C.S., Tan, H.J., Lee, Y.M., Chamhuri, N.S., Fadzil, F., Zolkaifli, N., Arulsamy, A., Thanabalan, J., Aledo-Serrano, A. and Cheong, W.L. (2024) ‘Role of HMGB1 in posttraumatic epilepsy and cognitive decline among traumatic brain injury patients: A prospective longitudinal study in Kuala Lumpur’, Research Square. doi: 10.21203/rs.3.rs-3950429/v1.
- Ngadimon, I.W., Seth, E.A. and Shaikh, M.F. (2024) ‘Exploring the

- neuroinflammatory pathway in epilepsy and cognitive impairment: Role of HMGB1 and translational challenges', Journal Name, (Volume, Issue). doi: 10.1186/s42494-024-00000-y.
- Novak, A., Vizjak, K. and Rakusa, M. (2022) 'Cognitive impairment in people with epilepsy', *Journal of Clinical Medicine*, 11(1). doi: 10.3390/jcm11010267.
- Oemijati, S., Setiabudy, R. and Budijanto, A. (1987) *Pedoman Etik Penelitian Kedokteran Indonesia*. 1st edn. Jakarta: Fakultas Kedokteran Universitas Indonesia.
- Okuma, Y., Saito, H., Fujimoto, S., Takahashi, H. and Matsumoto, M. (2012) 'Anti-high mobility group box-1 antibody therapy for traumatic brain injury', *Annals of Neurology*, 72(3), pp. 373–384. doi: 10.1002/ana.23602.
- Pascual, J., Jimenez, S., & Calleja, J. (2020) 'HMGB1 levels in epilepsy: influence of seizures and sex', *Epilepsy Research*, 163, pp. 106342.
- Paudel, Y.N., Shaikh, M.F., Chakraborti, A., Kumari, Y., Aledo-Serrano, Á., Aleksovska, K., Alvim, M.K.M. and Othman, I. (2018a) 'HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction', *Frontiers in Neuroscience*, 12(SEP), pp. 1–19. doi: 10.3389/fnins.2018.00628.
- Paudel, Y.N., Shaikh, M.F., Chakraborti, A., Kumari, Y., Aledo-Serrano, Á., Aleksovska, K., Alvim, M.K.M. and Othman, I. (2018b) 'HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction', *Frontiers in Neuroscience*, 12(SEP). doi: 10.3389/fnins.2018.00628.
- Paudel, Y.N., Shaikh, M.F., Chakraborti, A., Kumari, Y., Aledo-Serrano, Á., Aleksovska, K., Alvim, M.K.M. and Othman, I. (2019) 'High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: From pathogenesis to therapeutic approaches', *Journal of Neurochemistry*, 151(5), pp. 542–557. doi: 10.1111/jnc.14663.
- Perhimpunan Dokter Spesialis Saraf Indonesia (Perdossi) (2019) *Pedoman Tatalaksana Epilepsi*. Surabaya: Airlangga University Press.
- Perucca, E., Brodie, M.J., Kwan, P. and Tomson, T. (2023) 'Drug resistance in epilepsy', *The Lancet Neurology*, 22(8), pp. 723–734. doi: 10.1016/S1474-4422(23)00151-5.
- Poudel, P., Kafle, S.P. and Pokharel, R. (2021) 'Clinical profile and treatment

- outcome of epilepsy syndromes in children: A hospital-based study in Eastern Nepal', *Epilepsia Open*, 6(1), pp. 206–215. doi: 10.1002/epi4.12470.
- Price, S. and Wilson, L. (2016) Patofisiologi Konsep Klinis dan Proses-Proses Penyakit. 6th edn. Jakarta: Penerbit Buku Kedokteran EGC.
- Prinz, M., Jung, S. and Priller, J. (2019) 'Microglia biology: One century of evolving concepts', *Cell*, 179(2), pp. 292–311. doi: 10.1016/j.cell.2019.08.053.
- Quon, R.J., Lee, J., Park, H., Voegele, S. and Giardina, A. (2020) 'Antiepileptic drug effects on subjective and objective cognition', *Epilepsy and Behavior*, 104, p. 106906. doi: 10.1016/j.yebeh.2020.106906.
- Raghavan, S., Hark, T., & Gupta, P. (2018) 'Estrogen modulation of inflammatory response: role of HMGB1', *Journal of Endocrinology*, 237(3), pp. 133-144.
- Ravizza, T., Rizzi, M., Vezzani, A., Balosso, S., Aronica, E. and Liu, J. (2018) 'High mobility group box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy', *Brain, Behavior, and Immunity*, 72, pp. 14–21. doi: 10.1016/j.bbi.2017.10.008.
- Rubboli, G., Gardella, E., Balestrini, S., Pisano, T., Bisulli, F., Striano, P. and Casari, G. (2023) 'Variation in prognosis and treatment outcome in juvenile myoclonic epilepsy: A Biology of Juvenile Myoclonic Epilepsy Consortium proposal for a practical definition and stratified medicine classifications', *Brain Communications*, 5(3), pp. 1–18. doi: 10.1093/braincomms/fcad182.
- Salih, K.S., Hamdan, F.B. dan Al-Mayah, Q.S., 2020. Diagnostic value of matrix metalloproteinase-2 and high mobility group box 1 in patients with refractory epilepsy. *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 56, p.102.
- Sasaki, T., Kitagawa, T., Sato, T., Kamei, N. and Miura, Y. (2016) 'Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease', *Experimental Neurology*, 275, pp. 220–231. doi: 10.1016/j.expneurol.2015.11.003.
- Sayed, N.M., Aldin, M.T.K., Ali, S.E., Mohamed, A.G. and Abd El-Kareem, A. (2023) 'Cognitive functions and epilepsy-related characteristics in patients with generalized tonic-clonic epilepsy: A cross-sectional study', *Middle East Current Psychiatry*, 30(1), p. 15. doi: 10.1186/s43045-023-00293-6.
- Scheffer, I.E., Berkovic, S., Capovilla, G., Connolly, M.B., French, J., Guilhoto, L. and Hirsch, E. (2017) 'ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology', *Epilepsia*, 58(4), pp.

512–521. doi: 10.1111/epi.13709.

- Shi, Y., Zhang, H., Zhang, X., Chen, Y. and Zhang, J. (2018) ‘HMGB1 mediates microglia activation via the TLR4/NF-κB pathway in coriaria lactone-induced epilepsy’, *Molecular Medicine Reports*, 17(4), pp. 5125–5131. doi: 10.3892/mmr.2018.8485.
- Sigar, R.J., Kembuan, M.A.H. and Mahama, C.N. (2017) ‘Gambaran fungsi kognitif pada pasien epilepsi di poliklinik saraf RSUP Prof. Dr. R.D. Kandou Manado’, e-Journal UNSRAT, 5(2). doi: 10.35790/ecl.5.2.2017.18582.
- Simic, T., Steiner, G., Nagels, G., Lafosse, C. and Marien, P. (2022) ‘Cognitive training to enhance aphasia therapy (Co-TrEAT): A feasibility study’, *Frontiers in Rehabilitation Sciences*, 3(April), pp. 1–13. doi: 10.3389/fresc.2022.815780.
- Shorvon, S. D. (2011). *The causes of epilepsy: Common and uncommon causes in adults and children*. Cambridge University Press.
- Smolak, E., Hendriks, M.P., Broekhof, E., Fikke, L.J. and Koster, A. (2020) ‘Sustained attention in developmental language disorder and its relation to working memory and language’, *Journal of Speech, Language, and Hearing Research*, 63(12), pp. 4096–4108. doi: 10.1044/2020_JSLHR-20-00265.
- Sayed, N.M., Aldin, M.T.K., Ali, S.E. and Mohamed, A.G. (2023) ‘Cognitive functions and epilepsy-related characteristics in patients with generalized tonic-clonic epilepsy: A cross-sectional study’, *Middle East Current Psychiatry*, 30(1), p. 15. doi: 10.1186/s43045-023-00293-6.
- Stern, Y., 2012. Cognitive reserve in ageing and Alzheimer's disease. *Lancet Neurology*, 11(11), pp.1006-1012.
- Tan, S.W., Wang, P., Zhou, R. and Shen, J. (2021) ‘HMGB1 mediates cognitive impairment caused by the NLRP3 inflammasome in the late stage of traumatic brain injury’, *Journal of Neuroinflammation*, 18(1), pp. 1–16. doi: 10.1186/s12974-021-02274-0.
- Tedrus, G.M.A.S. (2020) ‘Cognitive and epilepsy’, *Dement Neuropsychol*, 14(2), pp. 186–193.
- Terrone, G., Balosso, S., Pauletti, A. and Ravizza, T. (2020) ‘Inflammation and reactive oxygen species as disease modifiers in epilepsy’, *Neuropharmacology*, 167. doi: 10.1016/j.neuropharm.2019.107742.
- Torres-Maravilla, E., Gonzalez-Cervantes, R.M., Jimenez-Ruiz, I. and Perez-Carrillo, E. (2021) ‘Role of gut microbiota and probiotics in colorectal cancer: Onset and

- progression', *Microorganisms*, 9(5). doi: 10.3390/microorganisms9051021.
- Thurman, D. J., Beghi, E., Begley, C. E., Berg, A. T., Buchhalter, J. R., Ding, D., & Hauser, W. A. (2011). Standards for epidemiologic studies and surveillance of epilepsy. *Epilepsia*, 52(7), 2-26.
- Vera-Gonzalez, A. (2023) 'Pathophysiological mechanisms underlying the etiologies of seizures and epilepsy', in *Epilepsy*. Brisbane: Exon Publications, p. 1.
- Videira, G., Cordeiro, L., Santos, M. and Oliveira, A. (2021) 'Female preponderance in genetic generalized epilepsies', *Seizure*, 91(March), pp. 167–171. doi: 10.1016/j.seizure.2021.06.014.
- Walker, L., Yap, P., Alexander, G. and Lawrence, J. (2014) 'High mobility group box 1 in the inflammatory pathogenesis of epilepsy: Profiling circulating levels after experimental and clinical seizures', *The Lancet*, 383, p. S105. doi: 10.1016/s0140-6736(14)60368-8.
- Wang, D., Li, H., Sun, L. and Zhang, J. (2017) 'Anti-high mobility group box-1 (HMGB1) antibody inhibits hemorrhage-induced brain injury and improves neurological deficits in rats', *Scientific Reports*, 7(November 2016), pp. 1–16. doi: 10.1038/srep46243.
- Wang, H., Ward, M.F. and Sama, A.E. (2014) 'Targeting HMGB1 in the treatment of sepsis', *Expert Opinion on Therapeutic Targets*, 18(3), pp. 257–268. doi: 10.1517/14728222.2014.863876.
- Wang, J., Feng, X., Zhang, L. and Wu, Q. (2015) 'Beta-1-adrenergic receptors mediate Nrf2-HO-1-HMGB1 axis regulation to attenuate hypoxia/reoxygenation-induced cardiomyocytes injury in vitro', *Cellular Physiology and Biochemistry*, 35(2), pp. 767–777. doi: 10.1159/000369736.
- Wang, J., Zhang, Y., Li, Y. and Sun, H. (2017) 'Epilepsy-associated genes', *Seizure*, 44, pp. 11–20. doi: 10.1016/j.seizure.2016.11.030.
- Wazema, D.H., Jemal, Y., Lemma, A. and Bekele, M. (2023) 'Magnitude of cognitive impairment among patients with epilepsy at health institutions in Gurage Zone, Ethiopia', *SAGE Open Nursing*, 9. doi: 10.1177/23779608231154400.
- Wen, Q., Liu, H., Yang, Y., Zhang, R. and Zhao, H. (2019) 'The release and activity of HMGB1 in ferroptosis', *Biochemical and Biophysical Research Communications*, 510(2), pp. 278–283. doi: 10.1016/j.bbrc.2019.01.090.
- Wieshmann, U., Baker, G.A., Stephenson, J. and Smith, D.F. (2012) 'Self-reported adverse effects of mono- and polytherapy for epilepsy', *Journal of Neurology*,

Neurosurgery & Psychiatry, 83(Suppl 2), p. A4.4-A5. doi: 10.1136/jnnp-2012-304200a.19.

- Yin, X.Y., Wang, F., Li, C. and Zhao, Q. (2023) 'HMGB1 mediates synaptic loss and cognitive impairment in an animal model of sepsis-associated encephalopathy', Journal of Neuroinflammation, 20(1), pp. 1–16. doi: 10.1186/s12974-023-02756-3.
- Yu, C., Deng, X.J. and Xu, D. (2023) 'Microglia in epilepsy', Neurobiology of Disease, 185(April). doi: 10.1016/j.nbd.2023.106249.
- Yu, J.Y. and Pearl, P.L. (2013) 'Metabolic causes of epileptic encephalopathy', Epilepsy Research and Treatment, 2013, pp. 1–20. doi: 10.1155/2013/124934.
- Yuan, L., Hu, X., Zhu, X., Wang, H. and Xu, J. (2018) 'The influence of gut microbiota dysbiosis to the efficacy of 5-fluorouracil treatment on colorectal cancer', Biomedicine and Pharmacotherapy, 108(August), pp. 184–193. doi: 10.1016/j.biopha.2018.08.165.
- Yuan, S., Li, T., Luo, X. and Huang, Z. (2020) 'High mobility group box 1 (HMGB1): A pivotal regulator of hematopoietic malignancies', Journal of Hematology and Oncology, 13(1), pp. 1–19. doi: 10.1186/s13045-020-00920-3.
- Zawar, I. (2023) Insights from comprehensive research on epilepsy and cognitive decline, NeurologyLive. Available at: <https://www.neurologylive.com/view/insights-from-comprehensive-research-on-epilepsy-and-cognitive-decline-ifrah-zawar-md> (Accessed: 14 October 2024).
- Zhang, S., Zhao, W., Zhu, Y., Xu, C. and Sun, Y. (2022) 'Role of HMGB1/TLR4 and IL-1 β /IL-1R1 signaling pathways in epilepsy', Frontiers in Neurology, 13(June), pp. 1–11. doi: 10.3389/fneur.2022.904225.
- Zhang, S., Liu, Y., Chen, H., and Wang, X., 2022. Cognitive functions in individuals with different levels of education. Journal of Cognitive Neuroscience, 34(5), pp.789-805.
- Zhao, J., Wang, J., Peng, Y., Li, T. and Qin, X. (2017) 'Therapeutic potential of an anti-high mobility group box-1 monoclonal antibody in epilepsy', Brain, Behavior, and Immunity, 64, pp. 308–319. doi: 10.1016/j.bbi.2017.02.002.